In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer/Regeneron: Typically Rich, Extra Regional

Executive Summary

Regeneron Pharmaceuticals' October 18th deal with Bayer is the perfect case-study for observers of today's biopharma sector: high-value, ex-US only, specialist, and with a nice split-indication twist in its tail.
Advertisement

Related Content

Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond
The Rise of Regional Dealmaking
The Rise of Regional Dealmaking
Bayer Wins Specialty CV Deal
Bigger Deal Values by Splitting Indications: PDL's Experience
Bigger Deal Values by Splitting Indications: PDL's Experience
OSI Buys Eyetech, Market Rubs Eyes
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas
The Anti-Global, Specialist Strategy: Why Bayer's Choice Might Be Right for Other Pharmas

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002673

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel